Epilepsy & CBD

Cannabidiol displays anti-epileptiform and anti-seizure properties in vitro and in vivo.

Posted by Joe Pavlik on

Published: J Pharmacol Exp Ther. 2010 Feb;332(2):569-77. doi: 10.1124/jpet.109.159145. Epub 2009 Nov 11. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. Jones NA, Hill AJ, Smith I, Bevan SA, Williams CM, Whalley BJ, Stephens GJ. Abstract Plant-derived cannabinoids (phytocannabinoids) are compounds with emerging therapeutic potential. Early studies suggested that cannabidiol (CBD) has anticonvulsant properties in animal models and reduced seizure frequency in limited human trials. Here, we examine the antiepileptiform and antiseizure potential of CBD using in vitro electrophysiology and an in vivo animal seizure model, respectively. CBD (0.01-100 muM) effects were assessed in vitro using the...

Read more →

The Utility of Cannabidiol in the Treatment of Refractory Epilepsy

Posted by Joe Pavlik on

Published: Clin Pharmacol Ther. 2016 Aug 10. doi: 10.1002/cpt.441. The Utility of Cannabidiol in the Treatment of Refractory Epilepsy. Reddy DS Abstract Cannabis-derived cannabinoids such as cannabidiol (CBD) have anticonvulsant properties. Recently, there has been an emerging interest in the use of CBD-enriched products for treatment of drug-resistant epilepsy. Some pilot trials of CBD have proved beneficial for refractory epilepsy, but its efficacy is yet to be confirmed by standard placebo-controlled trials. However, the mechanisms underlying the seizure protection efficacy claims of CBD remain unclear. This review briefly describes the clinical utility of CBD in the treatment of refractory epilepsy....

Read more →

From Cannabis to Cannabidiol to Treat Epilepsy, Where are we?

Posted by Joe Pavlik on

Published: Curr Pharm Des. 2016 Aug 31. From cannabis to cannabidiol to treat epilepsy, where are we? Lippiello P, Balestrini S, Leo A, Coppola A, Citraro R, Elia M, Russo E1, De Sarro G. Abstract BACKGROUND: Several antiepileptic drugs (AEDs), about 25, are currently clinically available for the treatment of patients with epilepsy. Despite this armamentarium and the many recently introduced AEDs, no major advances have been achieved considering the number of drug resistant patients, while many benefits have been indeed obtained for other clinical outcomes (e.g. better tolerability, less interactions). Cannabinoids have long been studied for their potential therapeutical...

Read more →

Cannabidiol: promise and pitfalls.

Posted by Joe Pavlik on

Published: Epilepsy Curr. 2014 Sep;14(5):250-2. doi: 10.5698/1535-7597-14.5.250. Cannabidiol: promise and pitfalls. Welty TE, Luebke A, Gidal BE Abstract Over the past few years, increasing public and political pressure has supported legalization of medical marijuana. One of the main thrusts in this effort has related to the treatment of refractory epilepsy-especially in children with Dravet syndrome-using cannabidiol (CBD). Despite initiatives in numerous states to at least legalize possession of CBD oil for treating epilepsy, little published evidence is available to prove or disprove the efficacy and safety of CBD in patients with epilepsy. This review highlights some of the basic science...

Read more →